Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps?

  1. Rossella Menghini1 and
  2. Massimo Federici1,2⇑
  1. 1Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
  2. 2Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy
  1. Corresponding author: Massimo Federici, federicm{at}uniroma2.it
Diabetes 2019 Feb; 68(2): 268-270. https://doi.org/10.2337/dbi18-0044
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Cardiovascular complications are the main cause of death in subjects with diabetes and represent an ever-growing burden on health care systems throughout the world, and especially in Western society (1). People with diabetes show a high incidence to develop atherosclerosis and major cardiovascular accidents as a consequence of the complex interactions among insulin resistance, hyperglycemia, and associated metabolic abnormalities (2). However, despite the considerable efforts that have been devoted to the understanding of the processes by which chronic hyperglycemia promotes the development and the progression of atherosclerosis, these processes have not been fully elucidated yet and novel ways to prevent development or treat macrovascular and microvascular diseases are of particular interest. Endothelial dysfunction is considered a crucial event in the pathogenesis of vascular disease in diabetes, and an early detection of cellular and molecular mechanisms related to the imbalance between damage of endothelial cells and their impaired repair may give rise to new and efficient preventive and therapeutic strategies (3).

Loss of endothelial cells due to increased cell death and impaired regeneration is a major contributor to the extent of endothelial dysfunction (4). Endothelium itself has a relatively weak capacity to self-repair due to low proliferative capacity. However, recently it has become evident that cells, recruited from the bone marrow and from other tissues, circulate in the peripheral blood and have the ability to promote reendothelialization after injury (5). In addition to classic endothelial progenitor cells, other hematopoietic lineage cells, such as M2-like macrophages or T lymphocytes, may support endothelium regeneration (6).

Several studies demonstrated that in vivo reendothelialization capacity is severely impaired in patients with diabetes (5,7,8). In this issue of Diabetes, Kuschnerus et al. (9) confirm the relevant role of M2-like macrophages in endothelium regeneration, showing in vivo that the endothelial regeneration potential of M2-like macrophages derived from patients with diabetes is severely impaired as a result of increased expression of microRNA (miR)-483-3p. Notably, the authors show a marked increased expression of miR-483-3p in the diabetic human vascular wall as well as in the carotid artery of diabetic mice (9). A therapeutic approach based on miR-483-3p inhibition through an LNA-based anti-miR enhances reendothelialization in vivo, suggesting that miR-483-3p inhibitors show promising therapeutic potential for the treatment of cardiovascular disease in patients with diabetes. In vitro modulation of miR-483-3p levels did not directly influence proliferation but did increase apoptosis in both endothelial and macrophage cells. Therefore, the mechanisms underlying the therapeutic benefit of LNA anti–miR-483-3p very likely involve a direct proregenerative effect on local endothelial cells adjacent to the injury and the ability to modulate M2-like macrophage signals to promote the regeneration of injured tissue (Fig. 1). miR-483-3p influences many biological processes, and it is deregulated in different types of cancer (10). The association of glucose metabolism to the regulation of miR-483-3p is supported by the fact that miR-483-3p maps at the INS-IGF2 locus, which is involved in the insulin pathway (11). Additionally, it was observed that miR-483-3p is abnormally expressed in diabetic cardiomyopathy and promotes apoptosis by targeting the IGF1 gene (12). miR-483-3p has been also reported to control angiogenesis in vitro by targeting the serum response factor, representing a potential therapeutic target for improving neovascularization in ischemic heart disease (13). The apoptotic effect of miR-483-3p is consistent with previous findings; however, the mechanisms by which miR-483-3p may be induced remained unclear because in the current study miR-483-3p expression was not affected by hyperglycemia and showed a strikingly different expression pattern when comparing endothelial and macrophage cells. This finding, added to the difficulties in defining the relevant target gene that is affected by miR-483-3p in the context of endothelium regeneration, points to cell-specific regulation pathways. Vascular endothelial zinc finger 1 (VEZF1) is a potential candidate to explain the link between miR-483-3p and reduced endothelial regeneration. The discovery of VEZF1 as an endothelial transcription factor and its role in angiogenesis is relatively new. Genetic knockout studies revealed the role of VEZF1 in vascularization; however, the mechanism of its regulation is not fully understood (14–17). Therefore, further studies are necessary to define the role of miR-483-3p and VEZF1 pathway in diabetes-induced vascular complications.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Potential therapeutic effect of LNA-based anti–miR-483-3p in reendothelialization.

Despite the limited mechanistic insights into the detailed functions of the miR-483-3p, the study by Kuschnerus et al. (9) provides many interesting aspects and highlights the central role of miR-483-3p in endothelium regeneration. Rapid endothelialization is essential for the development of vascular grafts (18). A rapidly growing approach is the insertion of miRNAs or antagomirs as drugs eluted from stents positioned in patients after balloon dilation of arteries (19). This is a potential therapeutic scenario that might change our ability to interfere with rapidly growing processes, such as restenosis, in vivo through the contextual effect on several genes obtained by few miRNAs or antagomirs in a very restricted area and manner. miR-483-3p is the new kid on the block in this promising area of molecular medicine.

Article Information

Acknowledgments. The authors wish to thank Dr. Giulia Iuliani (Department of Systems Medicine, University of Rome Tor Vergata) for her help with assembling Fig. 1.

Funding. Research by M.F. was partly funded by the Ministry of Education, University and Research (MIUR) Progetti di Ricerca di Interesse Nazionale (PRIN) protocol number 2015MPESJS_004.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, pp. 349.

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Rao Kondapally Seshasai S,
    2. Kaptoge S,
    3. Thompson A, et al.; Emerging Risk Factors Collaboration
    . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841pmid:21366474
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Martín-Timón I,
    2. Sevillano-Collantes C,
    3. Segura-Galindo A,
    4. Del Cañizo-Gómez FJ
    . Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes 2014;5:444–470pmid:25126392
    OpenUrlCrossRefPubMed
  3. ↵
    1. Schalkwijk CG,
    2. Stehouwer CD
    . Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;109:143–159pmid:16033329
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gilbert RE
    . Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 2013;77:849–856pmid:23503045
    OpenUrlCrossRefPubMed
  5. ↵
    1. Avogaro A,
    2. Albiero M,
    3. Menegazzo L,
    4. de Kreutzenberg S,
    5. Fadini GP
    . Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011;34(Suppl. 2):S285–S290pmid:21525470
    OpenUrlFREE Full Text
  6. ↵
    1. Rohde E,
    2. Malischnik C,
    3. Thaler D, et al
    . Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006;24:357–367pmid:16141361
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Sorrentino SA,
    2. Bahlmann FH,
    3. Besler C, et al
    . Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007;116:163–173pmid:17592079
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fadini GP,
    2. Miorin M,
    3. Facco M, et al
    . Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005;45:1449–1457pmid:15862417
    OpenUrlFREE Full Text
  9. ↵
    1. Kuschnerus K,
    2. Straessler ET,
    3. Müller MF,
    4. Lüscher TF,
    5. Landmesser U,
    6. Kränkel N
    . Increased expression of miR-483-3p impairs the vascular response to injury in type 2 diabetes. Diabetes 2019;68:349–360
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Pepe F,
    2. Visone R,
    3. Veronese A
    . The glucose-regulated miR-483-3p influences key signaling pathways in cancer. Cancers (Basel) 2018;10:E181pmid:29867024
    OpenUrlPubMed
  11. ↵
    1. Fu H,
    2. Tie Y,
    3. Xu C, et al
    . Identification of human fetal liver miRNAs by a novel method. FEBS Lett 2005;579:3849–3854pmid:15978578
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Qiao Y,
    2. Zhao Y,
    3. Liu Y, et al
    . miR-483-3p regulates hyperglycaemia-induced cardiomyocyte apoptosis in transgenic mice. Biochem Biophys Res Commun 2016;477:541–547pmid:27346130
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kong L,
    2. Hu N,
    3. Du X, et al
    . Upregulation of miR-483-3p contributes to endothelial progenitor cells dysfunction in deep vein thrombosis patients via SRF. J Transl Med 2016;14:23pmid:26801758
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kuhnert F,
    2. Campagnolo L,
    3. Xiong JW, et al
    . Dosage-dependent requirement for mouse Vezf1 in vascular system development. Dev Biol 2005;283:140–156pmid:15882861
    OpenUrlCrossRefPubMedWeb of Science
    1. Miyashita H,
    2. Kanemura M,
    3. Yamazaki T,
    4. Abe M,
    5. Sato Y
    . Vascular endothelial zinc finger 1 is involved in the regulation of angiogenesis: possible contribution of stathmin/OP18 as a downstream target gene. Arterioscler Thromb Vasc Biol 2004;24:878–884pmid:15031128
    OpenUrlAbstract/FREE Full Text
    1. Bruderer M,
    2. Alini M,
    3. Stoddart MJ
    . Role of HOXA9 and VEZF1 in endothelial biology. J Vasc Res 2013;50:265–278pmid:23921720
    OpenUrlCrossRefPubMed
  15. ↵
    1. AlAbdi L,
    2. He M,
    3. Yang Q,
    4. Norvil AB,
    5. Gowher H
    . The transcription factor Vezf1 represses the expression of the antiangiogenic factor Cited2 in endothelial cells. J Biol Chem 2018;293:11109–11118pmid:29794136
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Curcio A,
    2. Torella D,
    3. Indolfi C
    . Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011;75:1287–1296pmid:21532177
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Gareri C,
    2. De Rosa S,
    3. Indolfi C
    . MicroRNAs for restenosis and thrombosis after vascular injury. Circ Res 2016;118:1170–1184pmid:27034278
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 68 (2)

In this Issue

February 2019, 68(2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps?
Rossella Menghini, Massimo Federici
Diabetes Feb 2019, 68 (2) 268-270; DOI: 10.2337/dbi18-0044

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

MicroRNA Manipulation to Boost Endothelial Regeneration: Are We Ready for the Next Steps?
Rossella Menghini, Massimo Federici
Diabetes Feb 2019, 68 (2) 268-270; DOI: 10.2337/dbi18-0044
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.